Why Is ABSCI CORP (ABSI) Stock Up Today?

ABSI stock rose 12.39% to $11.88 on Monday. The primary driver for the move was Jefferies initiating coverage of the clinical-stage biopharmaceutical company with a Buy rating. The firm highlighted the potential of Absci’s hair loss drug as a key catalyst for the stock’s performance.

What Happened

Jefferies began tracking Absci with a Buy recommendation, citing the company’s pipeline in hair loss therapeutics. This initiation added to a broader wave of positive analyst sentiment surrounding the stock. Keybanc recently maintained an Overweight rating on Absci and raised its price target to $20. Additionally, HC Wainwright & Co. reiterated a Buy rating, maintaining a price target of $16.

Absci also announced it will participate in upcoming investor conferences. The company, which uses generative AI to design breakthrough therapeutics, is scheduled to present at these events to engage with the investment community. The stock’s recent momentum has been significant, with the shares moving 39.1% over the last eight sessions, climbing from $8.54 to the current level.

What The Data Shows

Absci has a market capitalization of $1.6 billion and remains unprofitable, with a trailing twelve-month EPS of -0.80. Revenue has declined 62.3% over the same period. The stock exhibits high volatility with a beta of 2.28. In the 52-week tape, the stock printed 34 fresh 52-week highs and one fresh 52-week low on October 28, 2026. The 52-week range spans from $2.24 to $12.05, indicating the stock is trading near its historical highs.

What To Watch

Investors will monitor Absci’s participation in upcoming investor conferences for further updates on its generative AI therapeutics. The stock’s recent surge and high beta suggest continued volatility as the market digests the new analyst coverage and the company’s clinical progress.